A Study of RO7821657 in Participants With Solid Tumors
A First In-Human, Multicenter, Phase I Clinical Study of RO7821657, a Protease Activated TCB Antibody That Targets CEACAM5, in Participants With Locally Advanced and/or Metastatic Solid Tumors
The aim of this study is to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics (PK), and evaluate pharmacodynamic and biomarker effects to support selection of the recommended Phase 2 dose(s) (RP2D[s])
The study consists of two parts, namely Part 1 and Part 2:
Part 1: Evaluation of RO7821657 as monotherapy in participants with microsatellite-stable (MSS) colorectal cancer (CRC).
Part 2: Evaluation of RO7821657 as monotherapy in participants with non-squamous non-small cell lung cancer (NSCLC)
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
Backup dei contatti dello studio
- Nome: Reference Study ID Number: BP46447 https://forpatients.roche.com/
- Numero di telefono: 888-662-6728
- Email: global-roche-genentech-trials@gene.com
Luoghi di studio
-
-
-
København Ø, Danimarca, 2100
- Reclutamento
- Rigshospitalet
-
-
-
-
-
Sutton, Regno Unito, SM2 5PT
- Reclutamento
- Royal Marsden Sutton
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Life expectancy estimated by the Investigator to be ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.
- Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; previously irradiated lesions are considered measurable if progression has been demonstrated in such lesions after the irradiation.
- Availability of archival tumor tissue or tissue obtained from a fresh biopsy at screening if formalin-fixed paraffin-embedded [FFPE]-preserved archival tissue is not available. The archival tumor tissue should come from a core biopsy, a punch biopsy, an excisional biopsy, or a surgical specimen. Lymph node biopsy, bone biopsy (unless from soft tissue), or fine needle aspiration are unacceptable for submission. Lesions that are intended to be biopsied should not be counted as target lesions.
- Adequate cardiovascular function:
New York Heart Association (NYHA) Heart Failure Class ≤ 1.
- Agreement to adhere to the contraception requirements.
Exclusion Criteria:
-
Participants with active Central Nervous System (CNS) metastases.
-
Any unresolved toxicities from prior therapy, i.e., radiotherapy, chemotherapy, targeted or checkpoint inhibitor therapy or surgical procedure, greater than CTCAE Grade 1 at the time of starting study treatment, except for alopecia and Grade 2 neuropathy.
a) Stable endocrine AEs managed with hormone replacement are permitted, including hypothyroidism on stable thyroid hormone replacement.
-
History of interstitial pulmonary disease, drug-induced pneumonitis, or evidence of active pneumonitis on screening computed tomography (CT) scan.
-
Participants with pulmonary miliary metastatic pattern (innumerable small lesions) or pulmonary lymphangitic carcinomatosis.
-
Active autoimmune disease that has required systemic treatment (except replacement treatment) within the last 2 years or any disease requiring immunosuppressive therapy while on study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Part 1A: Dose Escalation
Participants with MSS CRC will receive multiple doses of RO7821657 in single and multiple participant cohorts. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
Sperimentale: Part 1B: Backfill Cohorts
Participants with MSS CRC will receive RO7821657 at dosing regimen selected based on data from Part 1A. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
Sperimentale: Part 1C: Dose Expansion/Optimization
Participants with MSS CRC will receive RO7821657 at dosing regimens selected based on data from Parts 1A and 1B. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
Sperimentale: Part 2A: Abbreviated Dose Escalation
Participants with non-squamous NSCLC will receive multiple doses of RO7821657 in multiple participant cohorts. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
Sperimentale: Part 2B: Dose Expansion/Optimization
Participants with non-squamous NSCLC will receive RO7821657 at dosing regimen selected based on data from Part 2A. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Part 1: Incidence and Severity of Adverse Events (AEs)
Lasso di tempo: Up to approximately 27 months
|
AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any events of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria |
Up to approximately 27 months
|
|
Part 2: Incidence and Severity of Adverse Events (AEs)
Lasso di tempo: Up to approximately 27 months
|
AEs will be graded according to NCI CTCAE v5.0. Any events of CRS and ICANS will be graded based on the ASTCT criteria |
Up to approximately 27 months
|
|
Part 1A: Nature and Frequency of Dose-limiting Toxicities (DLTs)
Lasso di tempo: From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
|
|
Part 2A: Nature and Frequency of DLTs
Lasso di tempo: From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
|
|
Parts 1A and 1B: Recommended Phase 2 Dose (RP2D) Range of RO7821657
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
|
|
Part 2A: RP2D Range of RO7821657
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Parts 1 and 2: Serum Concentration of RO7821657
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Objective Response Rate (ORR)
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Disease Control Rate (DCR)
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Duration of Response (DoR)
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Progression-free Survival (PFS)
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: PFS Rate
Lasso di tempo: At 6 months
|
At 6 months
|
|
Parts 1 and 2: Overall Survival (OS) Rate
Lasso di tempo: At 6 months
|
At 6 months
|
|
Parts 1 and 2: Correlation of Baseline Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Tumor Expression With Clinical Activity
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Part 1B: Cluster of Differentiation 8 (CD8) Expression in Tumor Tissue
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Percentage of Participants With Presence, Frequency, Severity and Interference of Symptomatic Treatment Toxicities as Assessed by NCI Patient-reported Outcomes (PRO)-CTCAE
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Change From Baseline in Symptomatic Treatment Toxicities as Assessed by NCI PRO-CTCAE
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Percentage of Participants Troubled by Treatment Symptoms, as Assessed by Single Item European Organisation for Research and Treatment of Cancer Item Library 46 (EORTC IL46)
Lasso di tempo: Up to approximately 27 months
|
Up to approximately 27 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Clinical Trials, Hoffmann-La Roche
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- BP46447
- 2026-526150-14-00 (Ctis)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .